Feature ArticlesMedication use in autism spectrum disordersTreatment of autism is complex and involves a comprehensive educational interventional plan. |  | |
Feature ArticlesMedication reconciliation efforts meeting needs and showing promiseDespite the many challenges associated with implementation of a successful Med Rec program, the potential for significant value drives the ongoing effort to find scalable, cost-effective solutions. |  | |
Feature ArticlesNew initiatives arise out of NECC compounding tragedyThe impact that this sequence of events has had, is having, and will continue to have on the practice of pharmacy nationwide is of unprecedented magnitude and is of the utmost concern to practicing pharmacists everywhere. |  | |
Feature ArticlesReview of the pharmacologic arsenal for the war on obesityObesity has become a highly prevalent chronic condition that is associated with significant morbidity and mortality. |  | |
| Focus On... |
Ponatinib (Iclusig; Ariad Pharmaceuticals) is an oral tyrosine kinase inhibitor (TKI) that was approved by FDA on December 14, 2012, for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myelogenous leukemia (CML) that is resistant or intolerant to previous TKI therapy, and for Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (Ph+ALL).  |
| CLINICAL NEWS |
Because of the need for early detection, improved antiviral agents, and changes in the availability of commercial Hepatitis C virus (HCV) tests, the Centers for Disease Control and Prevention (CDC) has issued a new guidance for clinicians and laboratorians. Interim data from a phase 2, multicenter, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172 (Merck), for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection, was presented at the 2013 International Liver Congress, 48th annual meeting of the European Association for the Study of the Liver, in Amsterdam. Zoster vaccination was associated with a reduction in post-herpetic neuralgia among those who are aged 65 and older, according to a study, published in PLoS Medicine. However, they also found that the use of the shingles vaccine was also very low among certain population groups FDA has approved ezetimibe and atorvastatin (Liptruzet, Merck) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet, according to the manufacturer. Data from a meta-analysis of 5 boceprevir (Victrelis, Merck) phase 3 clinical studies was presented at the 2013 International Liver Congress, 48th annual meeting of the European Association for the Study of the Liver, in Amsterdam.  |
Formulary Journal archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.
